Transferring integrase technology to animals

描述(申请人提供)：我们已经开发了新技术 哺乳动物细胞中的定点整合。这项技术涉及使用 新型噬菌体整合酶在COMPACT中的高效整合 认可网站。酶识别的位置出现的频率很低 哺乳动物基因组，并可用于靶向整合。我们已经证实了这一点 在哺乳动物组织培养细胞中的技术，并准备转移到 动物。活体实验现在是应用 技术以改进现有的基因治疗方法和 转基因动物的构建。 拟议中的实验包括产生携带有 整合酶的识别位点。这些动物将被用于基因 治疗研究和改进创造转基因的基础技术 哺乳动物。我们将开展野生型、转基因和 流体力学方法将质粒DNA导入肝脏的疾病模型小鼠 尾静脉注射法。我们将运送一种携带该基因的质粒用于 噬菌体整合酶以及携带治疗基因的质粒和 整合酶的识别位点。该酶将介导特定部位的 将治疗性基因整合到基因组中由 酵素。我们将利用这项技术开发有效的永久性基因疗法。 A1-抗胰蛋白酶联合应用治疗肺气肿和血友病B 因子IX基因。这些实验的成功将导致这一点的应用 将创新技术应用于其他基因治疗环境并取得进展 在病人身上进行临床试验。

DESCRIPTION (provide by applicant): We have developed new technology for site-specific integration in mammalian cells. The technology involves use of novel phage integrases that mediate efficient integration at compact recognition sites. Sites recognized by the enzymes occur at low frequency in mammalian genomes and can be used to target integration. We have validated this technology in mammalian tissue culture cells, and it is ready for transfer to animals. In vivo experiments are now essential for application of the technology to improve existing methodologies for gene therapy and for construction of transgenic animals. The proposed experiments include the generation of transgenic mice that carry recognition sites for the integrases. These animals will be used for gene therapy studies and to improve basic technology for creation of transgenic mammals. We will carry out gene therapy studies in wild-type, transgenic, and disease model mice by introducing plasmid DNA to the liver by the hydrodynamic tail vein injection method. We will deliver a plasmid carrying the gene for a phage integrase along with a plasmid carrying the therapeutic gene and a recognition site for the integrase. The enzyme will mediate site-specific integration of the therapeutic gene into the genome at sites recognized by the enzyme. We will use this technology to develop effective permanent gene therapy treatments for emphysema and hemophilia B by introducing the a1-antitrypsin and factor IX genes. Success in these experiments will lead to application of this innovative technology to other gene therapy settings and progress toward clinical trials in patients.